Bioequivalency Study of Famciclovir 500 mg Tablets Under Fed Conditions

This study has been completed.
Information provided by:
Roxane Laboratories Identifier:
First received: March 21, 2011
Last updated: March 22, 2011
Last verified: March 2011
The objective of this study was to prove the bioequivalence of Famciclovir 500 mg Tablets under fed conditions.

Condition Intervention
Herpes Nos
Drug: famciclovir

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Famciclovir Tablets Under Fed Conditions

Resource links provided by NLM:

Further study details as provided by Roxane Laboratories:

Primary Outcome Measures:
  • bioequivalence determined by statistical comparison Cmax [ Time Frame: 8 days ] [ Designated as safety issue: No ]

Enrollment: 31
Study Start Date: July 2007
Study Completion Date: July 2007
Primary Completion Date: July 2007 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: famciclovir
    500 mg tablet
    Other Name: Famvir

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening

Exclusion Criteria:

  • Positive test for HIV, Hepatitis B, or Hepatitis C.
  • Treatment with known enzyme altering drugs.
  • History of allergic or adverse response to famciclovir, penciclovir or any comparable or similar product.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01321502

United States, New Jersey
Advanced Biomedical Research
Hackensack, New Jersey, United States, 07601
Sponsors and Collaborators
Roxane Laboratories
  More Information

Responsible Party: Elizabeth Ernst, Executive Director, Drug Regulatory and Medical Affairs, Roxane Laboratories, Inc. Identifier: NCT01321502     History of Changes
Other Study ID Numbers: FAMC-T500-PVFD-1 
Study First Received: March 21, 2011
Last Updated: March 22, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by Roxane Laboratories:
treatment of herpes

Additional relevant MeSH terms:
Anti-Infective Agents
Antiviral Agents processed this record on May 23, 2016